A detailed history of Janus Henderson Group PLC transactions in Siga Technologies Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 19,579 shares of SIGA stock, worth $165,050. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,579
Previous 19,789 1.06%
Holding current value
$165,050
Previous $169,000 12.43%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$6.32 - $10.46 $1,327 - $2,196
-210 Reduced 1.06%
19,579 $148,000
Q1 2024

May 15, 2024

BUY
$4.51 - $8.92 $22 - $44
5 Added 0.03%
19,789 $169,000
Q4 2023

Feb 14, 2024

SELL
$4.82 - $6.25 $173 - $225
-36 Reduced 0.18%
19,784 $110,000
Q3 2023

Nov 14, 2023

SELL
$4.32 - $5.77 $4 - $5
-1 Reduced 0.01%
19,820 $104,000
Q2 2023

Aug 14, 2023

SELL
$5.0 - $6.31 $656,120 - $828,023
-131,224 Reduced 86.88%
19,821 $100,000
Q1 2023

May 15, 2023

BUY
$5.23 - $8.42 $299,522 - $482,213
57,270 Added 61.07%
151,045 $868,000
Q4 2022

Feb 14, 2023

SELL
$7.29 - $10.14 $52,254 - $72,683
-7,168 Reduced 7.1%
93,775 $690,000
Q3 2022

Nov 14, 2022

BUY
$10.02 - $26.15 $20 - $52
2 Added 0.0%
100,943 $1.04 Million
Q2 2022

Aug 15, 2022

BUY
$6.5 - $13.68 $656,116 - $1.38 Million
100,941 New
100,941 $1.17 Million
Q1 2020

May 14, 2020

SELL
$3.99 - $5.46 $187,733 - $256,898
-47,051 Closed
0 $0
Q4 2019

Feb 18, 2020

BUY
$4.34 - $5.86 $10,628 - $14,351
2,449 Added 5.49%
47,051 $224,000
Q3 2019

Nov 14, 2019

BUY
$4.93 - $5.8 $29,875 - $35,148
6,060 Added 15.72%
44,602 $228,000
Q2 2019

Jul 31, 2019

BUY
$5.22 - $6.1 $201,189 - $235,106
38,542 New
38,542 $219,000

Others Institutions Holding SIGA

About SIGA TECHNOLOGIES INC


  • Ticker SIGA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 73,024,096
  • Market Cap $616M
  • Description
  • SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla T...
More about SIGA
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.